B
BIOSGN
vs
O
OMX Stockholm 30
Over the past 12 months, BIOSGN has underperformed OMX Stockholm 30, delivering a return of -30% compared to the OMX Stockholm 30's +17% growth.
Stocks Performance
BIOSGN vs OMX Stockholm 30
Performance Gap
BIOSGN vs OMX Stockholm 30
Performance By Year
BIOSGN vs OMX Stockholm 30
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Biosergen AB
Glance View
Biosergen AB operates as a biopharmaceutical company. The company is headquartered in Solna, Stockholm. The company went IPO on 2021-06-24. The company carries out biopharmaceutical research and development through its Subsidiary Biosergen AS from laboratory facilities in Trondheim, Norway and several other places worldwide. The firm is developing BSG005, a potentially disruptive antifungal drug which has demonstrated safety and potency advantages over competing antifungals. Biosergen initially aims BSG005 towards invasive fungal infections that claim the lives of hundreds of thousands of immune-compromised AIDS, cancer and transplant patients every year. At equal dose levels BSG005 has demonstrated a three-to-fouold potency advantage against the relevant fungal strains compared to the current standard of care, while being completely free of the kidney toxicity hampering other drugs in its class.